XM does not provide services to residents of the United States of America.
N
N

Novartis

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

India's Divi's Labs slides on risk of generic versions of top drug

BUZZ-India's Divi's Labs slides on risk of generic versions of top drug ** Shares of Divi's Laboratories DIVI.NS fall 4.2% to 4,656 rupees, the most on the Nifty 50 .NSEI ** Novartis NOVN.S loses initial bid to block generic versions of its top-selling heart drug Entresto, for which Divi's supplies pharma ingredients, or APIs ** Entresto is among l
N

Swiss stocks - Factors to watch on August 13

Swiss stocks - Factors to watch on August 13 ZURICH/GDANSK, Aug 13 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Tuesday: COMPANY STATEMENTS SCHINDLER HOLDING AG SCHP.S Wins Avenues - Riyadh project in Saudi Arabia. TECAN GROUP TECN.S Reports HY adjusted EBITDA of 67.9 million Swiss francs. NOVARTIS NOVN.S Lost initial bid to block generic of best-selling heart drug.
E
N
S

Novartis loses initial bid to block generic of best-selling heart drug

UPDATE 1-Novartis loses initial bid to block generic of best-selling heart drug Adds response from Novartis in paragraph 4 By Blake Brittain Aug 12 (Reuters) - Novartis NOVN.S failed to convince a federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a court decision issued on Monday.
N

Novartis loses initial bid to block generic of best-selling heart drug

Novartis loses initial bid to block generic of best-selling heart drug By Blake Brittain Aug 12 (Reuters) - Novartis NOVN.S failed to convince a Delaware federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a court decision issued on Monday. U.S.
N

Swiss stocks - Factors to watch on August 8

Swiss stocks - Factors to watch on August 8 ZURICH/GDANSK, Aug 8(Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: NOVARTIS NOVN.S Novartis Says Receives FDA Accelerated Approval For Fabhalta. ZURICH INSURANCE GROUP AG ZURN.S Zurich Insurance posted a better than expected rise in first-half business operating profit to $4.0 billion due to an ongoing robust performance in P&C, a record BOP in the Life business and excellent growth at Farmers, it said on Thursd
N
Z
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.